Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 1—January 2017
Dispatch

Increased Invasive Pneumococcal Disease, North East England, UK

Catherine Houseman, Gareth J. Hughes, Kaye E. Chapman, Deborah Wilson1, and Russell Gorton1Comments to Author 
Author affiliations: Public Health England, Newcastle upon Tyne, UK (C. Houseman, K.E. Chapman, D. Wilson, R. Gorton); Public Health England, Leeds, UK (G.J. Hughes)

Main Article

Table 2

Trends in incidence of serotypes causing invasive pneumococcal disease in North East England, April 2013–March 2016*

Serotype group, serotype IRR (95% CI)† p value†
PPV23–13
8 1.18 (1.08–1.29) <0.001
9N 1.19 (1.04–1.36) 0.009
10A 1.07 (0.89–1.29) 0.465
11A 1.03 (0.92–1.15) 0.617
12F 1.28 (1.20–1.36) <0.001
15B/C‡ 1.29 (0.99–1.69) 0.061
17F 0.84 (0.65–1.09) 0.188
20 1.12 (0.96–1.31) 0.148
22F 1.04 (0.95–1.13) 0.421
33F
1.17 (1.00–1.38)
0.051
NVT§
6C 1.00 (0.91–1.10) 0.958
15A 1.13 (1.07–1.19) <0.001
16F 0.99 (0.85–1.15) 0.924
23A 1.15 (1.06–1.24) <0.001
23B 1.06 (0.81–1.40) 0.657
24F 1.03 (0.91–1.17) 0.645
31 1.03 (0.92–1.16) 0.591
35B 1.12 (0.92–1.37) 0.256
35F 1.23 (1.06–1.44) 0.008
38 0.84 (0.61–1.15) 0.279

*Boldface indicates significance. IRR, incidence rate ratio; PPV23–13, 23–valent pneumococcal polysaccharide vaccine serotype cases, excluding those also contained in the 13–valent pneumococcal conjugate vaccine; NVT, nonvaccine type serotype cases.
†Increase in IRR per calendar quarter, estimated by using negative binomial regression, with counts per calendar quarter (from April 1–June 30, 2013 (Quarter 2) to January 1–March 31, 2016 (Quarter 1), robust standard errors and offset with the natural logarithm of the North East England population (10).
‡Includes 15B and 15B/C but excludes 15C serotypes as determined by the Public Health England Respiratory and Vaccine Preventable Bacteria Reference Unit.
§NVT serotypes reported more than once in the epidemiologic year 2015–2016.

Main Article

References
  1. Department of Health. Immunisation against infectious disease. The Green Book. 2012;25:295–313 [cited 2016 May 31]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147832/Green-Book-updated-140313.pdf
  2. Health & Social Care Information Centre. NHS Immunisation Statistics, England: 2014–2015 [cited 2016 Jul 19]. http://www.hscic.gov.uk/catalogue/PUB18472
  3. Public Health England. Pneumococcal polysaccharide vaccine (PPV): vaccine coverage estimates [cited 2016 Jul 19]. https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates
  4. Chapman  KE, Wilson  D, Gorton  R. Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England. Epidemiol Infect. 2013;141:34452. DOIPubMed
  5. Waight  PA, Andrews  NJ, Ladhani  SN, Sheppard  CL, Slack  MP, Miller  E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:53543. DOIPubMed
  6. Galanis  I, Lindstrand  A, Darenberg  J, Browall  S, Nannapaneni  P, Sjöström  K, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47:120818. DOIPubMed
  7. Moore  MR, Link-Gelles  R, Schaffner  W, Lynfield  R, Lexau  C, Bennett  NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:3019. DOIPubMed
  8. De Wals  P, Lefebvre  B, Markowski  F, Deceuninck  G, Defay  F, Douville-Fradet  M, et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine. 2014;32:15016. DOIPubMed
  9. Hughes  GJ, Wright  LB, Chapman  KE, Wilson  D, Gorton  R. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016;144:265469. https://doi.org/10.1017/S0950268816000856PubMed
  10. Kuster  SP, Tuite  AR, Kwong  JC, McGeer  A, Fisman  DN; Toronto Invasive Bacterial Diseases Network Investigators. Evaluation of coseasonality of influenza and invasive pneumococcal disease: results from prospective surveillance. PLoS Med. 2011;8:e1001042. DOIPubMed
  11. McCullers  JA, McAuley  JL, Browall  S, Iverson  AR, Boyd  KL, Henriques Normark  B. Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis. 2010;202:128795. DOIPubMed
  12. Pebody  R, Warburton  F, Andrews  N, Ellis  J, von Wissmann  B, Robertson  C, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill. 2015;20:30013. DOIPubMed
  13. Wyres  KL, Lambertsen  LM, Croucher  NJ, McGee  L, von Gottberg  A, Liñares  J, et al. Pneumococcal capsular switching: a historical perspective. J Infect Dis. 2013;207:43949. DOIPubMed
  14. Public Health England. Pneumococcal disease: guidance, data and analysis [cited 2016 May 31] https://www.gov.uk/government/collections/pneumococcal-disease-guidance-data-and-analysis

Main Article

1These authors were co-principal investigators.

Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external